Please assess the completion status of the following clinical trial:

Trial Title: Randomized Study to Reduce Calcineurininhibitor Toxicity in Pediatric and Adolescent Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age at inclusion 3-16 years~* male or female patients~* recipient of first or second renal transplant~* graft age \> 24 months~* last acute rejection episode \> 6 months ago~* Immune suppression comedication Mycophenolatmofetil (MMF) in a dose range of 1200 +/- 200 mg/m² BSA/d within at least 6 months or minimal MPA-AUC ≥ 45 mg x h/l. If MPA-AUC \< 45 mg x h/l adjustment of dosage with re-screening in ≥ 4 weeks is possible.~* Application of CSA in stable dosing within the last 3 months before study inclusion and CSA-C2-level \> 500 ng/ml. If CSA-C2-level \< 500 ng/ml adjustment of dosage with re-screening in ≥ 4 weeks is possible.~* steroid-free immunosuppression for at least 6 months before enrollment~* biopsy of the renal graft without any signs of acute rejection (def. according to BANFF classification), within 3 months before enrollment~* written informed consent of parents/legal guardians and, if applicable, patient's consent~Exclusion Criteria:~* glomerular filtration rate \< 40 ml/min/1.73 m2 BSA (acc. to Schwartz' formula) at time of enrollment~* \> 2 episodes of acute graft rejection within 12 months prior to enrollment~* condition after steroid-resistant graft rejection~* actual participation in another clinical trial~* Recurrence of primary renal disease in the graft~* proven infection with EBV and/ or CMV and antiviral therapy within 3 months prior to enrollment~* proven infection with polyoma virus within 3 months prior to enrolment~* pregnant or nursing women~* hemoglobin \< 8 g/dl at screening visit~* non-treated arterial hypertension~* uncontrolled infectious disease~* history of malignancy of any organ system, treated or non-treated

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: OTHER): Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).
- B (Type: NO_INTERVENTION): Standard CSA-dosing without reduction. Therapy control by C2-monitoring.

Based on this trial design, predict the completion outcome and termination type (if applicable).